| # | Title | Journal | Year | Citations |
|---|
| 1 | Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort | British Journal of Cancer | 2019 | 113 |
| 2 | Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer | JAMA Oncology | 2021 | 92 |
| 3 | Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial | Lancet Oncology, The | 2022 | 66 |
| 4 | Genomics to select treatment for patients with metastatic breast cancer | Nature | 2022 | 57 |
| 5 | RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study | | 2020 | 43 |
| 6 | Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial | Breast Cancer Research | 2019 | 42 |
| 7 | Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer | Clinical Chemistry | 2021 | 38 |
| 8 | Multicenter evaluation of breast cancer patients’ satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic | British Journal of Cancer | 2021 | 37 |
| 9 | Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial | Lancet Oncology, The | 2022 | 35 |
| 10 | Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer | Clinical Chemistry | 2020 | 33 |
| 11 | Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer | Npj Breast Cancer | 2021 | 33 |
| 12 | Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort | European Journal of Cancer | 2020 | 31 |
| 13 | Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data | Critical Reviews in Oncology/Hematology | 2019 | 30 |
| 14 | Selective treatment pressure in colon cancer drives the molecular profile of resistant circulating tumor cell clones | Molecular Cancer | 2021 | 30 |
| 15 | Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO’s adverse drug reactions database | Annals of the Rheumatic Diseases | 2022 | 26 |
| 16 | Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database | ESMO Open | 2021 | 22 |
| 17 | The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases | BMC Cancer | 2019 | 20 |
| 18 | High Levels of Cartilage Oligomeric Matrix Protein in the Serum of Breast Cancer Patients Can Serve as an Independent Prognostic Marker | Frontiers in Oncology | 2019 | 17 |
| 19 | Inflammatory Blood Markers as Prognostic and Predictive Factors in Early Breast Cancer Patients Receiving Neoadjuvant Chemotherapy | Cancers | 2020 | 17 |
| 20 | Impact of body mass index on overall survival in patients with metastatic breast cancer | Breast | 2021 | 17 |
| 21 | An epidemiology report for primary central nervous system tumors in adolescents and young adults: a nationwide population-based study in France, 2008–2013 | Neuro-Oncology | 2020 | 15 |
| 22 | Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network | Neuro-Oncology Practice | 2019 | 14 |
| 23 | Perioperative imaging in patients treated with resection of brain metastases: a survey by the European Association of Neuro-Oncology (EANO) Youngsters committee | BMC Cancer | 2020 | 14 |
| 24 | Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group | Clinical Genitourinary Cancer | 2020 | 12 |
| 25 | Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET) | Angiogenesis | 2020 | 11 |
| 26 | PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment | World Journal of Urology | 2020 | 11 |
| 27 | Atezolizumab plus modified DCF (docetaxel, cisplatin, and 5-fluorouracil) as first-line treatment for metastatic or locally advanced squamous cell anal carcinoma: A SCARCE-PRODIGE 60 randomized phase II study. | Journal of Clinical Oncology | 2022 | 11 |
| 28 | Detection of Circulating Tumor Cells in Cerebrospinal Fluid of Patients with Suspected Breast Cancer Leptomeningeal Metastases: A Prospective Study | Clinical Chemistry | 2022 | 10 |
| 29 | Complementary and alternative medicine use in glioma patients in France | Journal of Neuro-Oncology | 2019 | 8 |
| 30 | Serum glial fibrillary acidic protein is a predictor of brain metastases in patients with metastatic breast cancer | International Journal of Cancer | 2021 | 8 |
| 31 | Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG) | ESMO Open | 2022 | 8 |
| 32 | Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast Cancer | Cancers | 2022 | 8 |
| 33 | Liquid Biopsy and Immuno-Oncology for Advanced Nonsmall Cell Lung Cancer | Clinical Chemistry | 2023 | 8 |
| 34 | Detection of soluble biomarkers of pancreatic cancer in endoscopic ultrasound-guided fine-needle aspiration samples | Endoscopy | 2022 | 5 |
| 35 | A Phase II Multicenter Trial on High-Dose Vitamin D Supplementation for the Correction of Vitamin D Insufficiency in Patients with Breast Cancer Receiving Adjuvant Chemotherapy | Nutrients | 2021 | 5 |
| 36 | Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies | European Journal of Cancer | 2022 | 4 |
| 37 | 714P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) | Annals of Oncology | 2022 | 4 |
| 38 | Abstract GS4-08: Clinical utility of repeated circulating tumor cell (CTC) enumeration as early treatment monitoring tool in metastatic breast cancer (MBC) - a global pooled analysis with individual patient data | | 2021 | 2 |
| 39 | Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer | BMC Cancer | 2021 | 2 |
| 40 | Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database | Therapeutic Advances in Medical Oncology | 2022 | 2 |
| 41 | Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database | BMC Medicine | 2023 | 2 |
| 42 | CMET-26. PERIOPERATIVE IMAGING OF BRAIN METASTASES: A EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY (EANO) YOUNGSTERS SURVEY | Neuro-Oncology | 2018 | 0 |
| 43 | Abstract P2-01-12: Detection of circulating tumor cells in cerebrospinal fluid for patients with suspected breast cancer leptomeningeal metastases: A prospective study | Cancer Research | 2022 | 0 |
| 44 | Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort | Breast Cancer | 0 | 0 |
